◆ Ff-XT28s05_Abo_To (DRXT; iPS cells expressing the 3rd HLA in Japan※1)

Clone ID	Ff-XT28s05_ABo_To # 14-4	**Product**	Human iPS cells
Source	Peripheral Blood, Human	**Race**	Japanese
Passage No.	27	**Gender**	Male
Label Name	19A77	**Manufacture Dates**	May. 7th, 2019
Culture medium	StemFit AK03N	**Substrate**	iMatrix-511MG
Culture Method	Feeder-free (※2)		
Genome-editing techniques	CRISPR-Cas9 (※2)		
Use and Provision of this cell stock	Please check our web site ; https://www.cira-foundation.or.jp/e/project/index.html		

（※1）**Reference;** Okita, *et. al.*, Nat Methods. 2011 8(5): 409-412

（※2）**Reference;** Huaigeng Xu, et al. Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility. Cell Stem Cell. 2019 Apr 4;24(4):566-578.

For Research Use Only

Test Result

Test	Method	Result
Sterility	BacT/ALERT	Negative
Mycoplasma	PCR	Negative
Endotoxin	LAL	≦ 5 EU/mL
Morphology	Microscope	Consistent with human ES cells
STR genotyping	PCR	Consistent with the donor cells
Karyotype	G-banding	46,XY[20]
SNV/Indel(※3)	WES	No de-novo non-synonymous SNVs/Indels were found in COSMIC Cancer Gene Census (ver.88) and Shibata list (※4).
Gene editing confirmation	WES	Genome editing was detected on the HLA-A, HLA-B, and CIITA coding regions. An unintended SNV was detected on HLA-F.
Thawed postnatal cells	Counting the number of the cells (※5)	$2.17 \pm 0.13 \times 10^5$ cells （Survival rate ; 81±4 %）
Number of proliferating cells after thawing	Counting the number of the cells after culturing for 6 days(※5).	11.52×10^5 cells（Number of seeded cells : 0.97×10^5 cells）

（※3）SNV/Indel; Single nucleotide variants /Insertion Deletion

（※4）The PMDA Science Board “Current Perspective on Evaluation of Tumorigenicity of Cellular- and Tissue-based Products Derived from induced Pluripotent Stem Cells (iPSCs) and iPSCs as Their Starting Materials”（Cellular- and Tissue-based Products Subcommittee, 20 August 2013）

（※5）ThermoFisher Countess II®

■Image



Please contact us if you have any questions.

(ips-request@cira-foundation.or.jp)

CiRA Foundation